Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180002/S030

Zephyr Endobronchial Valve (EBV) System

Pulmonx Corporation · Decision date Mar 17, 2026

FDA DECISIONP180002/S030

What did the FDA decide?

FDA records P180002/S030 as a supplement to PMA P180002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 17, 2026.

FDA approval order statement

Removal of the ambient aeration step of the ethylene oxide (EO) sterilization process.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Anesthesiology
Decision date
Mar 17, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180002/S030
Regulatory pathway
PMA supplement
Product code
NJK
Decision code
OK30
Decision date
Mar 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Valve, pulmonary.

Product code
NJK
FDA device class
3

For the original device and its historical approval scope, see PMA P180002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180002 · Original PMA

    Zephyr Endobronchial Valve System

  2. P180002/S030 received

    Application receipt date recorded by FDA.

  3. P180002/S030 · FDA decision

    30-Day Notice

  4. P180002/S031 · Related supplement

    Zephyr Endobronchial Valve (EBV) System

  5. P180002/S032 · Related supplement

    Zephyr Endobronchial Valve System

Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180002

Product / regulatory recordCompanyPathwayDecision dateSource
Pulmonx CorporationPMA approvalJun 29, 2018FDA
Pulmonx CorporationPMA supplementJun 17, 2026FDA
Pulmonx CorporationPMA supplementSep 11, 2026FDA

Explore the linked device profile

Other records with product code NJK

Product / regulatory recordCompanyPathwayDecision dateSource
Gyrus Acmi, Inc.PMA supplementAug 20, 2026FDA
Gyrus Acmi, Inc.PMA supplementMay 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pulmonx Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
700 Chesapeake Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records